Fair Value Calculator Fair Value Calculator
EN DE

CRANEX (CRANEX) Fair Value & Analysis

IN · Market cap ₹770M

C CRANEX CRANEX · BSE
Price₹96.05
Fair Value₹51.11
Upside-46.8%
Quality52/100
Watch CRANEX for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹38.34 – ₹66.12

Fair value as of: Jul 5, 2026

From 15 valuation models · updated today

Share price +28.0% over the past month.

Price vs Fair Value (12 months)

₹108.56 ₹58.15 Fair Value ₹51.11 Jul 2025 Jul 2026

12‑month range ₹58.15 – ₹108.56 · fair‑value band ₹38.34 – ₹66.12 · the ₹96.05 price screens above the ₹51.11 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

CRANEX (CRANEX) currently trades at ₹96.05, while our model-based Fair Value estimate is ₹51.11 — implying the stock looks roughly 46.8% overvalued today. We read business quality at 52/100 (solid quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, CRANEX generated revenue of ₹318M at a net margin of 2.0%. Revenue grew 18.7% year over year. It earns a return on equity of 10.6%. Net debt stands at ₹208M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹38.34 (bear case) to ₹66.12 (bull case); at ₹96.05, the current price sits above that range. The share trades about 16% below its 52-week high and 72% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Revenue (TTM) ₹318M
Revenue growth (YoY) +18.7%
Net margin 2.0%
Return on equity 10.6%
Free cash flow −₹19.9M FY2026
P/E ratio 31.9
More key figures
Operating margin 8.4%
EPS (TTM) ₹3.01
EPS growth (YoY) +27.8%
Net debt ₹208M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

CRANEX reported revenue of ₹554M in FY2026 versus ₹401M in FY2022, a compound +8.4%/yr. Reported net income was ₹24.1M in FY2026, compounding +34.6%/yr from FY2022.

Revenue +8.4%/yr
FY22 ₹401M
FY23 ₹414M
FY24 ₹621M
FY25 ₹515M
FY26 ₹554M
Net income +34.6%/yr
FY22 ₹7.3M
FY23 ₹5.6M
FY24 ₹15.0M
FY25 ₹19.5M
FY26 ₹24.1M

Is CRANEX fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "CRANEX Fair Value". https://www.fairvalue-calculator.com/stock/CRANEX

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is CRANEX (CRANEX) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹51.11 versus a price of ₹96.05 — about −47% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CRANEX?
Our model-based fair value for CRANEX is ₹51.11 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹96.05.
What is the quality score of CRANEX?
CRANEX has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of CRANEX (CRANEX)?
CRANEX reported trailing-twelve-month revenue of about ₹318M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of CRANEX?
The net profit margin of CRANEX is about 2.0%, meaning it keeps roughly 2.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.